Published in J Pharmacokinet Biopharm on October 01, 1994
Use of dried blood spots in drug development: pharmacokinetic considerations. AAPS J (2010) 0.97
A mechanistic, model-based approach to safety assessment in clinical development. CPT Pharmacometrics Syst Pharmacol (2012) 0.97
Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model. CPT Pharmacometrics Syst Pharmacol (2016) 0.80
Use of probabilistic modeling within a physiologically based pharmacokinetic model to predict sulfamethazine residue withdrawal times in edible tissues in swine. Antimicrob Agents Chemother (2006) 0.80
Prediction of Deoxypodophyllotoxin Disposition in Mouse, Rat, Monkey, and Dog by Physiologically Based Pharmacokinetic Model and the Extrapolation to Human. Front Pharmacol (2016) 0.75
Impact of altered endogenous IgG on unspecific mAb clearance. J Pharmacokinet Pharmacodyn (2017) 0.75
Shortcomings in pharmacokinetic analysis by conceiving the body to exhibit properties of a single compartment. J Pharm Sci (1968) 4.58
Multiple insecticide resistance mechanisms in Anopheles gambiae and Culex quinquefasciatus from Benin, West Africa. Acta Trop (2007) 4.33
Modulation of the Escherichia coli sigmaE (RpoE) heat-shock transcription-factor activity by the RseA, RseB and RseC proteins. Mol Microbiol (1997) 3.51
Data from amplified fragment length polymorphism (AFLP) markers show indication of size homoplasy and of a relationship between degree of homoplasy and fragment size. Mol Ecol (2002) 3.38
Prevalence of myopia in the United States. Arch Ophthalmol (1983) 3.00
Is the risk of diabetic retinopathy greater in non-Hispanic blacks and Mexican Americans than in non-Hispanic whites with type 2 diabetes? A U.S. population study. Diabetes Care (1998) 2.97
Kinetics and stoichiometry of light-induced proton release and uptake from purple membrane fragments, Halobacterium halobium cell envelopes, and phospholipid vesicles containing oriented purple membrane. Biochim Biophys Acta (1976) 2.76
Economic costs of the foot and mouth disease outbreak in the United Kingdom in 2001. Rev Sci Tech (2002) 2.76
Alternative approaches to estimation of population pharmacokinetic parameters: comparison with the nonlinear mixed-effect model. Drug Metab Rev (1984) 2.65
Pharmacokinetic/pharmacodynamic modeling in drug development. Annu Rev Pharmacol Toxicol (2000) 2.61
The cellulosome: an exocellular, multiprotein complex specialized in cellulose degradation. Crit Rev Biochem Mol Biol (1996) 2.36
Clearance concepts in pharmacokinetics. J Pharmacokinet Biopharm (1973) 2.16
Isolation and characterization of human orthologs of yeast CCR4-NOT complex subunits. Nucleic Acids Res (2000) 2.13
Recognition specificity of the duplicated segments present in Clostridium thermocellum endoglucanase CelD and in the cellulosome-integrating protein CipA. J Bacteriol (1994) 2.12
Failure of passive zooprophylaxis: cattle ownership in Pakistan is associated with a higher prevalence of malaria. Trans R Soc Trop Med Hyg (1995) 2.11
Urinary excretion kinetics of amphetamine in man. J Pharm Pharmacol (1965) 2.11
Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans. Ann Intern Med (1973) 2.11
Application of salivary salicylate data to biopharmaceutical studies of salicylates. J Pharm Sci (1972) 2.10
Absorption kinetics of aspirin in man following oral administration of an aqueous solution. J Pharm Sci (1972) 2.08
Influence of route of administration on drug availability. J Pharm Sci (1972) 2.02
Conformation and motion of the choline head group in bilayers of dipalmitoyl-3-sn-phosphatidylcholine. Biochemistry (1975) 2.00
Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokinet Biopharm (1977) 1.87
Phenylbutazone-warfarin interaction in man: further stereochemical and metabolic considerations. Br J Clin Pharmacol (1983) 1.86
Nitrogen-containing ligands for asymmetric homogeneous and heterogeneous catalysis. Chem Rev (2000) 1.83
Concept of a volume of distribution and possible errors in evaluation of this parameter. J Pharm Sci (1968) 1.82
Anthropometric reference data and prevalence of overweight, United States, 1976-80. Vital Health Stat 11 (1987) 1.76
Intravenous cyclosporine kinetics in renal failure. Clin Pharmacol Ther (1983) 1.73
The photochemical cycle of bacteriorhodopsin. Fed Proc (1977) 1.71
Role of lipoproteins and erythrocytes in the in vitro binding and distribution of cyclosporin A in the blood. J Pharm Pharmacol (1982) 1.65
The use of population pharmacokinetics in drug development. Clin Pharmacokinet (1996) 1.62
Levels of filaggrin degradation products are influenced by both filaggrin genotype and atopic dermatitis severity. Allergy (2011) 1.59
Insecticide-treated bednets for the prevention of Plasmodium falciparum malaria in Cambodia: a cluster-randomized trial. Trop Med Int Health (2006) 1.58
A randomized controlled trial of insecticide-treated bednets and chaddars or top sheets, and residual spraying of interior rooms for the prevention of cutaneous leishmaniasis in Kabul, Afghanistan. Trans R Soc Trop Med Hyg (2000) 1.58
The indoor use of plastic sheeting pre-impregnated with insecticide for control of malaria vectors. Trop Med Int Health (2006) 1.53
Loss of protection with insecticide-treated nets against pyrethroid-resistant Culex quinquefasciatus mosquitoes once nets become holed: an experimental hut study. Parasit Vectors (2008) 1.53
Relationships between exposure to saquinavir monotherapy and antiviral response in HIV-positive patients. Clin Pharmacokinet (1999) 1.52
Best practice in the use of physiologically based pharmacokinetic modeling and simulation to address clinical pharmacology regulatory questions. Clin Pharmacol Ther (2012) 1.51
Pharmacokinetic perspectives on megadoses of ascorbic acid. Am J Clin Nutr (1997) 1.50
Acidosis in a patient with cholera: a need to redefine concepts. QJM (2004) 1.47
Perspectives in pharmacokinetics. Physiologically based pharmacokinetic modeling as a tool for drug development. J Pharmacokinet Biopharm (1995) 1.47
Subcellular localization of Clostridium thermocellum ORF3p, a protein carrying a receptor for the docking sequence borne by the catalytic components of the cellulosome. J Bacteriol (1994) 1.47
Biotransformation and distribution in blood of cyclosporine and its metabolites. Transplant Proc (1986) 1.42
Diffuse small intestinal lymphoid infiltration in nonimmunodeficient adults from Western Europe. Gastroenterology (1988) 1.40
Functions of S-layers. FEMS Microbiol Rev (1997) 1.38
Determination of acetylsalicylic acid and salicylic acid in plasma. J Pharm Sci (1967) 1.38
An evaluation of the integration of pharmacokinetic and pharmacodynamic principles in clinical drug development. Experience within Hoffmann La Roche. Clin Pharmacokinet (1997) 1.37
Role of modelling and simulation in Phase I drug development. Eur J Pharm Sci (2001) 1.33
Circumsporozoite genotyping of global isolates of Plasmodium vivax from dried blood specimens. J Clin Microbiol (1992) 1.33
Cyclosporin A: correlation between HPLC and RIA serum levels. Pharm Weekbl Sci (1982) 1.32
Disposition in male volunteers of a subanaesthetic intravenous dose of an oil in water emulsion of 14C-propofol. Xenobiotica (1988) 1.30
Insecticide-treated plastic tarpaulins for control of malaria vectors in refugee camps. Med Vet Entomol (2002) 1.29
Limitations to carbon 13-labeled urea breath testing for Helicobacter pylori in infants. J Pediatr (2001) 1.29
Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin Pharmacol Ther (1995) 1.28
Functional modeling of tight junctions in intestinal cell monolayers using polyethylene glycol oligomers. Am J Physiol Cell Physiol (2001) 1.26
Altered synaptic plasticity and memory formation in nitric oxide synthase inhibitor-treated rats. Proc Natl Acad Sci U S A (1993) 1.25
Intervention epidemiology training: a European perspective. Euro Surveill (2001) 1.25
Disposition of warfarin enantiomers and metabolites in patients during multiple dosing with rac-warfarin. Br J Clin Pharmacol (1994) 1.24
An entomological investigation of the likely impact of cattle ownership on malaria in an Afghan refugee camp in the North West Frontier Province of Pakistan. Med Vet Entomol (1994) 1.24
Stereospecific fluorescence high-performance liquid chromatographic analysis of warfarin and its metabolites in plasma and urine. J Pharm Sci (1984) 1.22
Simultaneous modeling of bopindolol kinetics and dynamics. Clin Pharmacol Ther (1984) 1.22
Stereochemical aspects of warfarin drug interactions: use of a combined pharmacokinetic-pharmacodynamic model. Clin Pharmacol Ther (1994) 1.21
Control of zoophilic malaria vectors by applying pyrethroid insecticides to cattle. Trop Med Int Health (1999) 1.19
Determination of lidocaine in blood and tissues. Anesthesiology (1973) 1.19
Disposition kinetics of lidocaine in normal subjects. Ann N Y Acad Sci (1971) 1.16
Comparative pathogenesis of acute and latent infections of calves with bovine herpesvirus types 1 and 5. Arch Virol (2001) 1.16
Chlorfenapyr: a pyrrole insecticide for the control of pyrethroid or DDT resistant Anopheles gambiae (Diptera: Culicidae) mosquitoes. Acta Trop (2007) 1.15
Two pictures of a lipid bilayer. A comparison between deuterium label and spin-label experiments. Biochemistry (1974) 1.14
The influence of heart failure, liver disease, and renal failure on the disposition of lidocaine in man. Am Heart J (1971) 1.13
Clinical pharmacology of recombinant human follicle-stimulating hormone. II. Single doses and steady state pharmacokinetics. Fertil Steril (1994) 1.13
Clinical pharmacology of recombinant human follicle-stimulating hormone (FSH). I. Comparative pharmacokinetics with urinary human FSH. Fertil Steril (1994) 1.13
Influence of congestive heart failure on blood vessels of lidocaine and its active monodeethylated metabolite. Clin Pharmacol Ther (1975) 1.12
Comparative pharmacokinetics of RAD001 (everolimus) in normal and tumor-bearing rodents. Cancer Chemother Pharmacol (2009) 1.12
Determination of tolbutamide and chlorpropamide in biological fluids. J Pharm Pharmacol (1973) 1.12
Cyclosporin-erythromycin interaction in renal transplant patients. Br J Clin Pharmacol (1989) 1.11
Distribution and spread of pyrethroid and DDT resistance among the Anopheles gambiae complex in Tanzania. Med Vet Entomol (2013) 1.10
A single point mutation in TFIIA suppresses NC2 requirement in vivo. EMBO J (2000) 1.10
Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans. Pharm Res (2000) 1.09
Application of salivary concentration data to pharmacokinetic studies with antipyrine. J Pharm Sci (1977) 1.09
High altitude epidemic malaria in Bamian province, central Afghanistan. East Mediterr Health J (2003) 1.08
[Chromosome aberrations produced in human lymphocytes by in vivo and in vitro irradiation]. C R Seances Soc Biol Fil (1985) 1.08
Plasma protein binding and therapeutic drug monitoring. Ther Drug Monit (1980) 1.07
Kinetic profiling of P-glycoprotein-mediated drug efflux in rat and human intestinal epithelia. J Pharmacol Exp Ther (2001) 1.06
Health care under the Taliban. Lancet (1997) 1.06
In vitro and in situ absorption of SDZ-RAD using a human intestinal cell line (Caco-2) and a single pass perfusion model in rats: comparison with rapamycin. Pharm Res (1998) 1.05
Pharmacokinetics of cyclosporin: influence of rate of constant intravenous infusion in renal transplant patients. Br J Clin Pharmacol (1987) 1.05
Comparative effects of ranitidine and cimetidine on the pharmacokinetics and pharmacodynamics of warfarin in man. Eur J Clin Pharmacol (1987) 1.05
Experimental hut evaluation of the pyrrole insecticide chlorfenapyr on bed nets for the control of Anopheles arabiensis and Culex quinquefasciatus. Trop Med Int Health (2008) 1.05
Protein binding and drug clearance. Clin Pharmacokinet (1984) 1.05
Routine mobilization of the splenic flexure is not necessary during anterior resection for rectal cancer. Dis Colon Rectum (2007) 1.04
Tissue water content in rats measured by desiccation. J Pharmacol Toxicol Methods (1997) 1.04
Chloroquine resistance in Pakistan and the upsurge of falciparum malaria in Pakistani and Afghan refugee populations. Ann Trop Med Parasitol (1997) 1.04
External counting and scintiphotography in rabbits with arthritis. Arthritis Rheum (1969) 1.04
The role of physiologically based pharmacokinetic modeling in regulatory review. Clin Pharmacol Ther (2012) 1.04
Caffeine ingestion elevates plasma insulin response in humans during an oral glucose tolerance test. Can J Physiol Pharmacol (2001) 1.04
Physiologically based pharmacokinetics of cyclosporine A: extension to tissue distribution kinetics in rats and scale-up to human. J Pharmacol Exp Ther (1998) 1.03
Lidocaine disposition kinetics in monkey and man. I. Prediction by a perfusion model. Clin Pharmacol Ther (1974) 1.03
Acyclovir prophylaxis of recurrent genital herpes: randomised placebo controlled crossover study. Genitourin Med (1985) 1.02